Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a probiotic during pregnancy help babies grow stronger?

NCT ID NCT07134790

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a probiotic called VE818 can reduce harmful gut bacteria and improve gut health in pregnant women. The trial involves 144 women in Bangladesh, Pakistan, Zambia, and Burkina Faso who are in their first or early second trimester. Participants first take an antibiotic (vancomycin) to clear bad bacteria, then receive either VE818 or a placebo to see if the probiotic helps restore a healthier gut.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VE818 (a mix of 11 beneficial bacteria) and oral vancomycin
What this could lead to
If it works, this could point toward a way to improve gut health in pregnant women, potentially reducing malnutrition and stunting in their babies.
What could go wrong
This is an early phase 2 proof-of-concept trial with only 144 participants, so results may not apply broadly. The probiotic may not effectively displace harmful bacteria, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

All pregnant women in their first or early second trimester of pregnancy, residing in the icddr,b service area of Matlab, who meet the eligibility criteria decribed below. Inclusion criteria 1. Women aged 18 years or older in their first or early second trimester of pregnancy (13-17 weeks of gestational age \[GA\]), living in defined geographical areas of Bangladesh (Matlab), Pakistan, Zambia, and Burkina Faso, where it can be assumed that environmental enteropathy is prevalent AND 2. Presence of any 2 out of 11 selected bacterial pathogen targets (Aeromonas, Campylobacter coli, Campylobacter jejuni, Campylobacter Pan, Enteroaggregative Escherichia coli, Enteropathogenic Escherichia coli, Enterotoxigenic Escherichia coli, Plesiomonas, Shigella\_EIEC, Salmonella and Klebsiella pneumoniae in fecal samples measured by TAC-qPCR. AND 3. Presence of any of the following WASH conditions - 1\. use surface water, unimproved water, or limited water for drinking; OR 2. use surface water, unimproved water, or limited water for cooking; OR 3. use surface water, unimproved water, or limited water for washing utensils; OR 4. practice open defecation, use unimproved sanitation (toilet facility), or limited sanitation (toilet facility); OR 5. lack facility or have limited facility for handwashing Exclusion criteria Potential participants will not be enrolled if they: 1. have MUAC ≥30 cm 2. are carrying more than one fetus (i.e., multiple pregnancy) 3. have diarrhea, defined as the passage of three or more loose stools per 24 hours, or have had diarrhea in the preceding 14 days 4. have fever or an active infection 5. have taken antibiotics or probiotics in the preceding 14 days 6. have taken steroids or non-steroidal anti-inflammatory drugs in the preceding 14 days 7. have severe anemia as determined using finger stick Hb \< 8 g/dl 8. have a history of chronic digestive disease 9. have any gastrointestinal contraindication to ingestion of a capsule (known or suspected gastrointestinal obstruction, stricture, fistula, gastroparesis, or any swallowing disorder) 10. have known immunocompromised status (known history of HIV infection, autoimmune disease, diabetes mellitus, etc.) 11. have known drug hypersensitivity/allergy/intolerance 12. have chronic disease or any other illness or condition which in the opinion of the investigator will complicate the assessment of safety or efficacy 13. are medically disqualified: Any potential participant who is deemed medically unfit for trial enrollment by a non-study healthcare provider, due to the presence of severe or unstable health conditions that could compromise safety or interfere with the study outcomes, will be excluded from participation 14. have a plan to observe fast any time during the intervention period 15. have a plan to leave the study area within the follow-up period 16. are participating in any other interventional trial 17. belong to a household from which another woman is already enrolled in the study but may be enrolled if/when these disqualifiers have expired.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Environmental enteric dysfunction (EED) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Agence de Formation de Recherche et d'Expertise en Santé pour l'Afrique

    RECRUITING

    Bobo-Dioulasso, Burkina Faso

More trials for these conditions

Other studies related to the condition(s) this trial covers.